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Abstract
The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, was investigated on the
development of reperfusion-induced arrhythmias and it was compared to their blood glucose lowering action. Arrhythmias were produced
by reperfusion following 6 min coronary artery ligation in anaesthetised rats. Glimepiride pretreatment 0.001–0.01–0.1–5.0 mgrkg i.p.,
.30 min before coronary occlusion significantly decreased the incidence of irreversible ventricular fibrillation and increased the survival
 .  .rate during reperfusion 64%, 61%, 60%, and 67% vs. 27% in controls . Glibenclamide produced similar effect 81% survival only in a
dose of 5 mgrkg, while smaller doses were ineffective. The minimal hypoglycaemic dose and the dose required to inhibit significantly
 .the oral glucose loading-induced hyperglycaemia were similar 1 and 0.1 mgrkg, respectively after glibenclamide and glimepiride. It is
concluded that although the blood glucose lowering potency of glibenclamide and glimepiride is rather similar, glimepiride appears to be
more potent than glibenclamide in preventing reperfusion-induced cardiac arrhythmias. q 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
q  .ATP-dependent K channels K were first de-ATP
 .scribed by Noma 1983 and have been found to be widely
distributed particularly in pancreatic b-cells, myocardium,
skeletal muscle, vascular smooth muscle cells and in neu-
rones. In cardiac cells they may play a special role because
of their high density at the cell surface, their large ion
conductance and their dependence upon cell metabolism.
Under normoxic conditions when ATP is available, these
channels are in a closed state. However, during ischaemia,
the decrease in cytosolic ATP concentration and the accu-
mulation of ischaemic metabolites together results in open-
ing of K channels. Several investigations have sug-ATP
gested that the activation of these channels during myocar-
dial ischaemia provides a ‘natural’ protective effect
 .Escande and Cavero, 1992; Grover, 1994 via increasing
the rate of repolarisation, thereby decreasing voltage de-
pendent calcium influx to the myocardium and preserving
ATP during ischaemia. On the other hand, opening of
K channels during the acute phase of myocardial in-ATP
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farction may contribute to the development of re-entrant
type arrhythmias and sudden cardiac death.
In isolated perfused hearts during regional ischaemia
andror reperfusion glibenclamide, a K -channel blocker,ATP
was found to be antiarrhythmic Wolleben et al., 1989;
Kantor et al., 1990; Tosaki et al., 1993; D’Alonzo et al.,
.1994 , and increased the chance for spontaneous recovery
from ventricular fibrillation Bril et al., 1992; Rees and
.Curtis, 1995 . There are also some in vivo investigations
showing that glibenclamide may possess antiarrhythmic
activity Ballagi-Pordany et al., 1990; Bekheit et al., 1990;
.Billman et al., 1993; Kondo et al., 1996 . However, con-
trary results have also been presented. For example,
glibenclamide had no effect on the incidence of ventricular
fibrillation developing in response to a secondary insult in
anaesthetized dogs with recent myocardial infarction Chi
.et al., 1989 , or in vitro against reperfusion-induced ar-
 .rhythmias Cole et al., 1991; Bernauer, 1997 . Previously,
we demonstrated in in vivo conditions that glibenclamide
pretreatment increased the survival rate and decreased the
incidence of life-threatening arrhythmias during acute my-
 .ocardial infarction in conscious rats Lepran et al., 1996´
or during ischaemiarreperfusion in anaesthetised rats
 .Baczko et al., 1997a .´
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Structurally different sulphonylureas may have a differ-
ent action against arrhythmias during myocardial is-
chaemia. It has been demonstrated by Ballagi-Pordany et
 .al. 1990 that first-generation antidiabetic sulphonylureas
may exacerbate arrhythmias, while second-generation
compounds produce antiarrhythmic action both in experi-
mental animals and in diabetic patients. The discovery of
the heterogeneity of sulphonylurea receptors, as part of
 .K channels Aguilar-Bryan et al., 1998 , further em-ATP
phasizes the need to compare the pancreatic and extrapan-
creatic effects of different agents.
Glimepiride is an orally active sulphonylurea derivative,
which is considered to be a more potent antidiabetic when
compared to glibenclamide Geisen, 1988; Langtry and
.Balfour, 1998 , while producing less adverse effects in the
 .cardiovascular system Geisen et al., 1996 . The aim of the
present investigations was to compare the efficacy of
glibenclamide and glimepiride in coronary artery occlu-
sion–reperfusion-induced arrhythmias in rats and to exam-
ine whether there is a correlation between this effect and
the hypoglycaemic action of these two K channelATP
inhibitory drugs.
2. Materials and methods
2.1. Animals
Male Sprague–Dawley rats, weighing 300–350 g were
used. Animals were fed a standard laboratory rat food
 .pellet Altromin, Godollo, Hungary and allowed to drink¨ ¨ ¨
tap water ad libitum. The animals were handled according
to a protocol reviewed and approved by the Ethical Com-
mittee for the Protection of Animals in Research of the
Albert Szent-Gyorgyi Medical University Szeged, Hun-¨
.gary .
2.2. Blood glucose determination
In conscious rats, a single drop of blood was taken by
cutting the tip of the tail. Blood glucose concentration was
measured using a med-strip test One Touch II, Lifescan,
.Johnson & Johnson, USA . A series of blood samples were
taken before treatment, 30 min after intraperitoneal drug
treatment and 30 min after oral administration of 1 grkg
glucose in 5 mlrkg tap water.
2.3. Coronary artery ligation and reperfusion
Coronary artery ligation and reperfusion was performed
 .as described earlier Baczko et al., 1997b . Animals were´
anaesthetised with pentobarbitone 60 mgrkg i.p. in a
.volume of 2 mlrkg . The left carotid artery was cannu-
lated for measuring the blood pressure using a pressure
transducer Gould-Statham P23ID, Hugo Sachs Elektronik,
.March-Hugstetten, Germany and was recorded on an os-
cillographic recorder Watanabe, WTR 331, Hugo Sachs
.Elektronik . The catheter was filled with saline that con-
 .tained heparin 500 IUrml , but the animal was not hep-
arinized. The trachea was cannulated for artificial respira-
tion. The chest was opened in the fourth intercostal space,
the heart was exposed and a loose loop of atraumatic silk
 .Ethibond 5r0, Ethicon, UK was placed around the left
main coronary artery, approximately 2 mm from its origin.
Both ends of the ligature were led out of the thoracic
cavity through a flexible tubing. The heart was set back in
its place and artificial respiration was started using 60
strokesrmin Harvard rodent ventilator, Model 683, Har-
.vard Apparatus, South Natick, MA, USA . The standard
 .electrocardiogram lead II, ECG was recorded using sub-
cutaneous needle electrodes. After finishing the prepara-
tion, the animals were allowed to stabilize for 10 min, then
the loose loop of the coronary artery ligature was tightened
and fixed by clamping on the silk and thus regional
myocardial ischaemia was produced for 6 min and then
followed by reperfusion for 5 min.
Incidence of arrhythmias was analysed in accordance
 .with the Lambeth Conventions Walker et al., 1988 , i.e.,
as ventricular fibrillation, ventricular tachycardia and other
types of arrhythmias, including single extrasystoles,
bigeminy and salvos. In case of ventricular fibrillation
development, no attempt was made to defibrillate the
animals.
At the termination of the experiment, heparin 500
.IUrkg was given intravenously and the heart was excised.
The left coronary artery was re-tightened and the heart was
first perfused retrogradely with 10 ml isotonic NaCl solu-
tion then with 2 ml ethanol, for the demarcation of the
occluded and the non-occluded myocardium Lepran et al.,´
.1983 . The non-perfusable area, that remained red coloured,
was cut along the epicardially visible border zone and its
weight was measured and expressed in percentage of the
wet weight of the ventricles. Hearts showing no arrhyth-
mias during coronary artery ligation or reperfusion and
exhibiting -10% non-perfusable area were excluded from
the final evaluation. Using these criteria altogether eight
animals were excluded from the experiments.
2.4. Drug administration protocol
 .Glibenclamide Sigma-Aldrich, Hungary or glimepiride
 .Hoechst, Germany was dissolved in dimethyl sulfoxide:
isotonic saline 1:1 mixture and was applied intraperi-
toneally 30 min prior to coronary artery ligation. To reduce
the solvent effect, the volume of the injection was 100
mlrkg. Control animals were given the same volume of
the solvent.
2.5. Statistical e˝aluation
The percentage incidence of arrhythmias was calculated
and compared using the x 2-method. All other parameters
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Table 1
Effect of glibenclamide and glimepiride on the blood glucose level
 .mmolrl after oral glucose loading in rats
Group Dose Basal Glucose
 .mgrkg loading
Control 3.2"0.16 5.4"0.26
Glibenclamide 0.01 3.2"0.11 5.7"0.17
a0.1 3.0"0.15 4.4"0.21
a1.0 3.3"0.08 3.4"0.18
Glimepiride 0.01 3.1"0.16 5.9"0.18
a0.1 3.2"0.04 4.0"0.11
a1.0 3.5"0.06 3.8"0.19
Results are mean"S.E. of six animals in each group.
 .Blood glucose concentration was measured before treatment Basal and
 .30 min after oral administration of 1 grkg glucose Glucose loading .
aP -0.05 compared to the corresponding control value.
were expressed as mean"standard error of the mean
 . S.E. and, after analysis of variance ANOVA with re-
peated measures for the blood pressure and heart rate
. values , were compared by the modified t-statistic Wal-
.lenstein et al., 1980 .
3. Results
3.1. Blood glucose le˝el
During basal conditions, i.e., before any drug treatment,
the blood glucose level in conscious rats was not signifi-
 .cantly different among different groups Table 1 . Thirty
minutes after the intraperitoneal administration, both
glibenclamide and glimepiride significantly reduced the
blood glucose concentration when applied in a dose of 1
mgrkg 2.6"0.12 and 2.7"0.11 mmolrl in the gliben-
clamide and glimepiride treated animals, vs. 3.3"0.08
and 3.5"0.06 mmolrl before treatment, respectively, P
.-0.05 . Both compounds already in a dose of 0.1 mgrkg
inhibited the elevation of plasma glucose concentration
after oral glucose loading, while the smallest dose applied
 .  .0.01 mgrkg was without effect Table 1 .
3.2. Haemodynamic parameters
At the doses that did not influence the blood glucose
concentration in conscious rats, neither glibenclamide nor
glimepiride pretreatment influenced significantly the heart
rate or blood pressure as measured before coronary artery
 .ligation in anaesthetised rats Table 2 . These haemody-
namic parameters did not differ from the control during
coronary artery ligation. Large doses of either gliben-
 .clamide or glimepiride i.e., 5 mgrkg i.p. , however,
significantly increased the heart rate before coronary artery
ligation and this remained high also during the experiment
 .after glimepiride pretreatment Table 2 . It was difficult to
measure the heart rate or blood pressure during reperfu-
sion, due to frequent arrhythmias in this period. When it
was possible to perform statistical analysis, no significant
differences were observed after glibenclamide or
glimepiride pretreatment as compared to the control group.
3.3. Arrhythmias during coronary artery ligation
In the present experiments, coronary artery ligation
lasting for 6 min was not enough to develop severe,
ischaemia-induced arrhythmias. There were no significant
differences among different treatments concerning the inci-
dence of arrhythmias or the survival rate during coronary
ligation.
3.4. Arrhythmias during reperfusion
Arrhythmias induced by reperfusion after 6 min my-
ocardial ischaemia started within 10–30 s following the
release of the coronary artery ligature. Irreversible ventric-
Table 2
 .  .Effect of glibenclamide and glimepiride on the heart rate HR and mean arterial blood pressure BP in anaesthetised rats
Group Dose Basal Occlusion Reperfusion
 .mgrkg n1 HR BP n2 HR BP n3 HR BP
Control 26 389"7.5 110"3.8 22 374"8.5 80"7.2 6 450"27.6 86"14.7
Glibenclamide 0.01 16 379"9.1 105"5.1 13 364"9.4 73"5.6 4 ND ND
0.1 15 392"6.1 104"4.8 15 385"7.9 73"4.7 8 429"21.3 94"9.5
a a5.0 20 432"7.5 104"5.5 16 398"15.3 49"4.8 13 432"11.6 89"9.6
Glimepiride 0.0001 9 337"9.0 121"6.7 8 312"10.9 72"11.7 3 ND ND
0.001 23 384"12.4 109"3.6 22 369"15.1 78"7.8 14 398"23.5 92"8.4
0.01 19 386"6.8 107"5.2 18 369"8.4 79"7.6 11 382"12.1 110"9.4
0.1 15 396"7.1 105"8.1 15 376"12.8 74"10.6 9 374"11.5 92"9.2
a a5.0 22 428"7.7 108"4.6 18 415"9.8 87"5.5 12 429"13.2 102"7.5
 .Results are mean"S.E. of the animals surviving the given period n1, n2 and n3 means the number of these animals, respectively .
 .  .  .Heart rate HR and mean arterial blood pressure was measured before coronary artery ligation Basal , 5 min after coronary ligation Occlusion and 5 min
 .after the release of occlusion Reperfusion . NDsNot determined because of few surviving animals.
aP-0.05 compared to the corresponding control value.
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Table 3
Effect of glibenclamide and glimepiride on the incidence of arrhythmias during reperfusion after 6 min coronary artery ligation in anaesthetised rats
 .Group Dose N Survived Incidence of arrhythmias %
 .  .mgrkg % None RevVF IrrevVF VT Other
Control 22 27 0 9 73 100 100
aGlibenclamide 0.01 13 31 0 8 69 100 62
0.1 15 53 0 33 47 87 100
a a a5.0 16 81 0 75 19 100 94
Glimepiride 0.0001 8 38 0 37 63 100 100
a a0.001 22 64 5 32 36 91 96
a a0.01 18 61 0 11 39 100 89
a a0.1 15 60 0 13 40 93 100
a a a5.0 18 67 0 50 33 100 72
NsTotal number of animals at the beginning of reperfusion; Nonesno arrhythmia developed; RevVFs reversible ventricular fibrillation; IrrevVFs
irreversible ventricular fibrillation; VTsventricular tachycardia; Othersventricular extrasystoles, bigeminy, and salvo.
aP-0.05 compared to the corresponding control value.
ular fibrillation occurred in 73% of the control animals and
there was no animal surviving without developing arrhyth-
 .mias during reperfusion Table 3 . Only 2 of 18 animals
recovered spontaneously from ventricular fibrillation in the
control group. Both glibenclamide and glimepiride in-
creased the survival rate during reperfusion after 6 min
myocardial ischaemia in anaesthetised rats and this protec-
tive effect of glimepiride was significant after using smaller
 .doses 0.01 and 0.001 mgrkg, Table 3 .
Both glibenclamide and glimepiride decreased signifi-
cantly the incidence of irreversible ventricular fibrillation
occurring during reperfusion after 6 min coronary occlu-
sion. However, the dose required to produce this effect
 .was much smaller with glimepiride i.e., 0.001–0.1 mgrkg
 .than with glibenclamide 5 mgrkg, Table 3 . The inci-
dence of ventricular tachycardia and other types of arrhyth-
mias did not show a dose related change after the pretreat-
ments.
The length of arrhythmic attacks was also measured in
the animals surviving reperfusion. As compared to the
control animals, neither glibenclamide nor glimepiride
treatment decreased the mean length of arrhythmic attacks
or the total period that was characterized by arrhythmias
during reperfusion.
4. Discussion
Transient coronary artery ligation followed by reperfu-
sion in the anaesthetised rat is a widely used and accepted
method to investigate the efficacy of antiarrhythmic treat-
ments. In the present investigations, we applied 6 min
occlusion of the left main coronary artery that was not
long enough for a significant amount of ischaemia-induced
arrhythmias to develop, however, it was purposely chosen
to prime the heart to develop severe arrhythmias consis-
tently 10–30 s following the start of reperfusion.
The present results demonstrate that pretreatment with
two sulphonylureas, glibenclamide or glimepiride, signifi-
cantly decreased the incidence of irreversible ventricular
fibrillation during reperfusion following a brief period of
myocardial ischaemia in anaesthetised rats. Moreover, this
cardioprotective action of glimepiride occurred in smaller
doses than that producing a blood glucose lowering effect.
It has been suggested that sulphonylureas may inhibit
the opening of K channels during myocardial is-ATP
chaemia, thereby preventing the loss of intracellular Kq
from jeopardised cells and the non-uniform shortening of
the action potential during myocardial ischaemia Mac-
.Kenzie et al., 1993; Tweedie et al., 1993 . Such an effect
by K inhibitors, like glibenclamide or glimepiride,ATP
could decrease the development of electric inhomogeneity
between the ischaemic and non-ischaemic myocardium
and might suppress the substrate for re-entrant pathways,
resulting in antiarrhythmic, antifibrillatory action. Such an
idea is supported by many investigators using gliben-
clamide in various in vitro Pogatsa et al., 1988; Wolleben
et al., 1989; Kantor et al., 1990; Tosaki et al., 1993;
.D’Alonzo et al., 1994 , as well as under in vivo experi-
mental conditions Bekheit et al., 1990; Billman et al.,
.1993; Kondo et al., 1996 .
Very few data are available on the possible antiarrhyth-
 .mic effect of glimepiride. Vegh and Papp 1996 have
found that only glimepiride but not glibenclamide attenu-
ated the number of episodes and the incidence of ventricu-
lar tachycardia during ischaemia after coronary artery liga-
tion in anaesthetised dogs. Our present investigations cor-
roborate these findings and support that, in a wide dose
range, glimepiride provides a more potent antiarrhythmic
effect than glibenclamide.
The reason for the observed difference between gliben-
clamide and glimepiride, and the divergence of the blood
glucose lowering potency and the ‘antiarrhythmic’ activity
is not known. However, there are some data that also
describe differences in the various actions of these two
 .compounds. Ozaki et al. 1992 found that glimepiride
inhibited the cyclooxygenase pathway of isolated human
platelets, while the activities of 12-lipoxygenase and phos-
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pholipase A were not influenced. On the other hand,2
glibenclamide inhibited both the cyclooxygenase and 12-
lipoxygenase enzymes and also the phospholipase A .2
 .Muller et al. 1994 described that glimepiride, in spite of
its higher blood glucose lowering potency in diabetic
patients than that of glibenclamide, had a 2.5–3-fold lower
affinity to membranes isolated from rat pancreatic b-cells.
 .Bijlstra et al. 1996 found that forearm vasodilator re-
sponse to the administration of the specific K channelATP
opener diazoxide was significantly inhibited by therapeutic
concentrations of glibenclamide, while glimepiride was
devoid of such effect. Perhaps, differences in the effects on
membrane currents or in direct metabolic effects, not
related to the increased secretion of insulin, e.g., increased
glucogenolysis, decreased fatty acid metabolism reviewed
.by Schotborgh and Wilde, 1997 , could be related to the
more pronounced ‘antifibrillatory’ action of glimepiride
than that of glibenclamide. The observed difference in the
blood glucose lowering and the ‘antiarrhythmic’ activity of
sulphonylurea compounds may also correlate with the
multiplicity of sulphonylurea receptors that regulate the
opening of ATP-dependent Kq channels. The contribution
of these possibilities to the difference between gliben-
clamide and glimepiride revealed in the present study
needs further investigations.
The observed differences between the two sulphony-
lurea compounds may suggest the possibility to develop
‘cardioselective’ compounds that inhibit K -channelsATP
without decreasing blood glucose level. This conclusion is
supported by recent findings that a novel ‘cardioselective’
K antagonist, HMR 1883 reduced the incidence ofATP
ventricular fibrillation, induced by 2 min coronary artery
occlusion during submaximal exercise test in mongrel dogs
 .with healed myocardial infarction Billman et al., 1998 .
Such compounds may be possible candidates for the drug
treatment of cardiac arrhythmias with a selective action
during myocardial ischaemia.
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